What this study is
This study is being done to determine the most effective dose of medicine to use to initially provide effective pain relief within the first 30 minutes of receiving an epidural for pain labor during labor. The study team will also study any side effects related to the epidural medication and patients' satisfaction with the quality of pain relief after receiving the epidural.
What's being tested
- Ropivacaine + Fentanyl
Intervention · DRUG
A standard epidural admixture - 0.1% Ropivacaine + 2 mcg/ml fentanyl - will be used.
Study details
- Official title
- Determination of the 90% Effective Volume (ED90) of Epidural 0.1% Ropivacaine and Fentanyl for Labor Analgesia Initiation in Patients Receiving a Dural-Puncture Epidural Technique
- Sponsor
- University of California, San Francisco
- Conditions
- Pregnancy · Labor and Delivery · Labor Analgesia
- Enrolling
- 50 people
- Starts
- 2025-10-24
- Est. completion
- 2026-07-31
- Design
- Open-label, single group, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex FEMALEHealthy volunteers Not acceptedYou may qualify if
- Patients with singleton vertex pregnancies in active labor (latent or spontaneous labor or after induction of labor)
- Cervical dilatation between 2 and 7 cm
- Requesting neuraxial labor analgesia
- Age 18 or older
You can't join if
- Significant obstetric disease (e.g., pre-eclampsia, major cardiac disease)
- Chronic pain or chronic opioid use
- BMI ≥ 50
- Multiple gestations
- Allergy or anaphylaxis to local anesthetic
- Fetal compromise or non-reassuring fetal trace
- Age under 18
- Inability to speak and understand English or Spanish
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of California, San Francisco
San Francisco, California, United States
- Alexander Butwick · Contact415-514-3757alexander.butwick@ucsf.edu
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 25-43988
Principal investigator
Alexander Butwick, MBBS, FRCA, MS
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.